RHI Magnesita 2025 Full Year Results: Disciplined Execution and Strong H2 Performance Deliver Resilient Earnings in Challenging Market Environment March 2, 2026 RHI Magnesita, the leading global supplier of high-grade refractory products, systems and solutions, announces its results for the year ended 31 December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302341332/en/ A resilient financial performance – in line with expectations Against a challenging market backdrop, RHI Magnesita delivered a performance in line [...]
SES: Full Year 2025 Results March 2, 2026 SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the year ended 31 December 2025 FY25 Performance (€ million) 2025 as reported (1) 2024 as reported (1) ∆ at constant FX (2) 2025 like-for-like (3) 2024 like-for-like (3) ∆ at constant FX (2) Average €/$ FX rate 1.12 1.09 [...]
Fluidra Delivers Strong 2025 Results, Advancing Its Strategic Priorities February 26, 2026 Sales up 7% on constant currency to €2,184 million with volume growth across all regions and positive price contribution Net income of €176 million, up 28% Successful completion of the €100 million savings set under its Simplification Plan Proposes 2025 dividend distribution of 65 euro cents per share, up 8%
Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle February 26, 2026 12M 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225107874/en/ Excellent momentum and record operating profit Total business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever Shareholders’ core net income advances 10.9 [...]
Indra Group Exceeds All Its Guidances in 2025 and Sets Even More Ambitious Guidances for 2026 Than Those Set Out in Its ‘Leading the Future’ Strategic Plan February 25, 2026 Results in fiscal year 2025 Revenues increased by 13%, totaling €5.457 billion in 2025 Indra Group sets financial guidances at least 17% higher than those foreseen in its Strategic Plan for 2026 Indra Group announces the payment of a €0.30 dividend per share (more than 20% above the dividend in 2024) charged to the earnings posted in 2025 The results and the increase in the order intake confirm Indra Group’s industrial strength and its capacity to tackle and execute the major defence modernization programs
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 February 25, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast [...]
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025 February 25, 2026 Strong margin improvement to 16.3% in FY 2025 Positive growth outlook with continued margin expansion in 2026 New EUR 200 million share buyback
Luxfer Delivers Strong Full-Year 2025 Profitability and Cash Generation February 24, 2026 Portfolio focus and favorable mix drive sustained profitability, enhanced adjusted earnings growth and strong cash flow generation Fourth Quarter 2025 Highlights* Net Sales declined 12.3% to $90.7 million from $103.4 million, while Adjusted Net Sales1 declined 5.5% Net Income of $0.1 million, compared to $3.3 million, and $0.12 per diluted share, with Adjusted Diluted EPS1 of $0.28 down 3.4% from $0.29 Adjusted EBITDA1 of $13.0 million, declined 5.8% Continued execution of previously announced operational excellence initiatives, including the Riverside and Powders Saxonburg centers of excellence, expected to drive improved efficiency and generate approximately $6 million of long-term annual savings Full Year 2025 Highlights* Net Sales declined 1.9% to $384.6 million from $391.9 million, while Adjusted Net Sales1 increased 2.5% Net Income of $13.1 million, or $0.48 per diluted share, compared to $18.3 million and $0.68 per diluted share, with Adjusted Diluted EPS1 of $1.11, up 12.1% from $0.99 Adjusted EBITDA1 of $51.9 million, up 4.2% Delivered strong free cash flow of $26.2 million, reducing net debt to $31.1 million Enhanced portfolio quality and strategic focus following completion of the Graphic Arts sale * Comparative information is relative to prior-year fourth quarter and full year; results exclude discontinued operations 1 Note: Adjusted results exclude Graphic Arts and 2024 legal fee recoveries
IGI Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results and Declares Ordinary Common Share Dividend February 24, 2026 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the fourth quarter and full year 2025. Highlights for the fourth quarter and full year 2025 include: (in millions of U.S. Dollars, except percentages and per share information) Quarter Ended December 31, Year Ended December 31, 2025 [...]
Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.